Reviewer's report

Title: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

Version: 2 Date: 7 November 2014

Reviewer: Vincent LAUNAY-VACHER

Reviewer's report:

Minor essential revisions.

This is a very interesting and important research report on the renal safety of everolimus in RCC.

1) I would suggest to replace TK inhibitor in the Keywords by mTOR inhibitor.

2) Page 6 line 20: pharmacological

3) Page 8 line 1: "regarded a P-values < 0.05..." delete "a"

4) Page 8 line 13: "83 patients had decreased renal function" please define what you mean by "decreased renal function". Lower than ?? ml/min ? ml/min/1,73m2 ?

5) Page 11 line 4: "... nephrologists should be alerted..."

6) Page 12 line 17-18: please note that mTOR inhibitors are not anti-angiogenic drugs as such, although they show anti)angiogenic effects as part of their mode of action.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests